Novocure Partners With Verastem Oncology on Pancreatic Cancer Trial

• Novocure entered a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate a combination treatment for locally advanced pancreatic cancer.
• The trial will combine Tumor Treating Fields therapy with chemotherapy and VS-7375, Verastem's investigational oral KRAS G12D inhibitor.
• Enrollment is expected to begin in 2027, targeting approximately 25 patients.
• Researchers will assess safety and tolerability, with preliminary efficacy evaluated as exploratory endpoints.
• Under the agreement, Novocure will manage and fund trial operations; Verastem will supply VS-7375.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610280700BIZWIRE_USPR_____20261028_BW077167) on October 28, 2026, and is solely responsible for the information contained therein.